{ "run": { "id": "cmnr15apy06iup6587po5goft", "region": "US", "assetId": "cmnr15ao006ihp658q9xl3rq7", "ticker": "TMO", "snapshotId": "cmnr15aoh06ilp65893fzqn25", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:57.374Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15aoh06ilp65893fzqn25", "assetId": "cmnr15ao006ihp658q9xl3rq7", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 502, "price": 503.46, "dayLow": 499.73, "volume": 1507956, "dayHigh": 507.275, "currency": "USD", "prevClose": 489.5, "week52Low": 385.46, "week52High": 643.99 }, "fundamentals": { "pe": 32.6083286437817, "beta": 0.859180531501153, "epsTTM": 17.77, "fcfTTM": 5509000000, "growth": { "epsYoy": 0.07177322074788911, "revenueYoy": 0.03911005387252501 }, "sector": "Measuring & Controlling Devices, NEC", "margins": { "net": 0.144702842377261, "gross": 0.1188238978936653, "operating": 0.1798606217210868 }, "website": "https://www.thermofisher.com/", "industry": "Laboratory equipment", "pegRatio": 4.54324444465461, "ebitdaTTM": 10949000000, "forwardPe": 23.5166396103896, "marketCap": 154038987000, "totalCash": 1106000000, "totalDebt": 18148000000, "debtEquity": 0.799614282771921, "quickRatio": 0.9348931841302136, "revenueTTM": 25542000000, "companyName": "THERMO FISHER SCIENTIFIC INC.", "priceToBook": 2.29577999873889, "currentRatio": 1.685147507629705, "dividendYield": 0.00297547317462159, "returnOnAssets": 0.06647960284912584, "returnOnEquity": 0.125526616361151, "analystOpinions": null, "businessSummary": "Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).", "enterpriseValue": 251305650000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 125000, "sharesOutstanding": 371484244, "enterpriseToEbitda": 22.95238377934058, "analystTargetMedian": null, "enterpriseToRevenue": 9.838918252290345, "operatingCashflowTTM": 7818000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:57.329Z" }, "results": [ { "id": "cmnr15aq006iwp658jk0u6uwy", "runId": "cmnr15apy06iup6587po5goft", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"TMO\",\"currency\":\"USD\",\"current_price\":503.46,\"target_price_6m\":530,\"target_price_12m\":555,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"High-quality life sciences compounder with durable competitive moats\",\"Post-COVID normalization largely complete; organic growth gradually reaccelerating\",\"Strong FCF generation (~$5.5B TTM) supports deleveraging and bolt-on M&A\",\"Forward PE of ~23.5x reasonable for mid-single-digit revenue growth profile\",\"Significant debt load ($18B) and macro uncertainty temper near-term upside\"],\"key_drivers\":[{\"driver\":\"Biopharma end-market recovery driving instrument and consumables demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Recurring revenue mix (~80%) underpins earnings stability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin expansion via PPI business system and pricing power\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Strategic M&A track record adding complementary capabilities\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FCF deployment optionality (buybacks, acquisitions, debt paydown)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Macro/tariff uncertainty impacting capital equipment spending\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"High leverage ($18B debt) limits financial flexibility if downturn deepens\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"PEG ratio of 4.5x signals growth already priced in at current multiple\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"FX headwinds from strong USD on ~50% international revenue\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Trade policy escalation or tariffs on scientific instruments/reagent imports\",\"Biotech funding downturn reducing customer CapEx and consumables demand\",\"Integration risk from future large-scale acquisitions\",\"Debt refinancing at higher rates compressing free cash flow\",\"Regulatory changes in pharma reducing R&D spend by key customers\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.235,\"wacc\":0.085,\"terminal_multiple\":25},\"scenarios\":{\"bear\":{\"target_price\":420,\"prob\":0.20,\"notes\":\"Macro recession compresses multiples to ~20x fwd PE; organic growth stalls near 1-2%.\"},\"base\":{\"target_price\":555,\"prob\":0.55,\"notes\":\"Mid-single-digit organic growth, margin expansion to ~23.5%; 25x fwd PE on ~$22 EPS.\"},\"bull\":{\"target_price\":650,\"prob\":0.25,\"notes\":\"Biopharma recovery accelerates; accretive M&A drives EPS to $24+; multiple re-rates to 27x.\"}},\"method_notes\":\"Valuation anchored on forward PE approach: base ~$22 fwd EPS x 25x = $550. Cross-checked with EV/EBITDA (~21-23x) and FCF yield (~3.5%). Snapshot gross margin (11.9%) appears anomalous vs typical TMO ~42%; likely a data artifact—did not override snapshot. Sell-side consensus not used as numeric input. 12M expected return ~10%, supporting BUY. Confidence moderate given macro uncertainty, tariff risks, and elevated PEG. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ai-equity-research-v1", "risks": [ "Trade policy escalation or tariffs on scientific instruments/reagent imports", "Biotech funding downturn reducing customer CapEx and consumables demand", "Integration risk from future large-scale acquisitions", "Debt refinancing at higher rates compressing free cash flow", "Regulatory changes in pharma reducing R&D spend by key customers" ], "ticker": "TMO", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Mid-single-digit organic growth, margin expansion to ~23.5%; 25x fwd PE on ~$22 EPS.", "target_price": 555 }, "bear": { "prob": 0.2, "notes": "Macro recession compresses multiples to ~20x fwd PE; organic growth stalls near 1-2%.", "target_price": 420 }, "bull": { "prob": 0.25, "notes": "Biopharma recovery accelerates; accretive M&A drives EPS to $24+; multiple re-rates to 27x.", "target_price": 650 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.055, "terminal_multiple": 25, "ebit_margin_target": 0.235 }, "key_drivers": [ { "driver": "Biopharma end-market recovery driving instrument and consumables demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Recurring revenue mix (~80%) underpins earnings stability", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin expansion via PPI business system and pricing power", "impact": "MED", "direction": "POS" }, { "driver": "Strategic M&A track record adding complementary capabilities", "impact": "MED", "direction": "POS" }, { "driver": "FCF deployment optionality (buybacks, acquisitions, debt paydown)", "impact": "MED", "direction": "POS" }, { "driver": "Macro/tariff uncertainty impacting capital equipment spending", "impact": "HIGH", "direction": "NEG" }, { "driver": "High leverage ($18B debt) limits financial flexibility if downturn deepens", "impact": "MED", "direction": "NEG" }, { "driver": "PEG ratio of 4.5x signals growth already priced in at current multiple", "impact": "MED", "direction": "NEG" }, { "driver": "FX headwinds from strong USD on ~50% international revenue", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation anchored on forward PE approach: base ~$22 fwd EPS x 25x = $550. Cross-checked with EV/EBITDA (~21-23x) and FCF yield (~3.5%). Snapshot gross margin (11.9%) appears anomalous vs typical TMO ~42%; likely a data artifact—did not override snapshot. Sell-side consensus not used as numeric input. 12M expected return ~10%, supporting BUY. Confidence moderate given macro uncertainty, tariff risks, and elevated PEG. Not investment advice.", "current_price": 503.46, "recommendation": "BUY", "thesis_bullets": [ "High-quality life sciences compounder with durable competitive moats", "Post-COVID normalization largely complete; organic growth gradually reaccelerating", "Strong FCF generation (~$5.5B TTM) supports deleveraging and bolt-on M&A", "Forward PE of ~23.5x reasonable for mid-single-digit revenue growth profile", "Significant debt load ($18B) and macro uncertainty temper near-term upside" ], "target_price_6m": 530, "target_price_12m": 555 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 45665, "createdAt": "2026-04-09T05:21:57.374Z", "usage": { "inputTokens": 3676, "outputTokens": 2047, "costUsd": 0.069555 } }, { "id": "cmnr15aq006izp6587eqelkhr", "runId": "cmnr15apy06iup6587po5goft", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research_Analyst\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"TMO\",\n \"currency\": \"USD\",\n \"current_price\": 503.46,\n \"target_price_6m\": 490,\n \"target_price_12m\": 480,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Steady revenue growth in life sciences sector.\",\n \"High valuation multiples relative to earnings growth.\",\n \"Strong market position and diversified portfolio.\",\n \"Moderate margin expansion potential exists.\",\n \"Balanced risk-reward at current price levels.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Biopharma industry growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operating margin stability\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"High P/E and PEG ratios\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Debt levels and interest rates\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Technological innovation in lab equipment\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory environment in healthcare\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Global economic conditions affecting spending\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Economic downturn reducing capital expenditure.\",\n \"Increased competition eroding market share.\",\n \"Regulatory changes impacting operations.\",\n \"Rising interest rates increasing debt costs.\",\n \"Execution risks from acquisitions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.07,\n \"terminal_multiple\": 20\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 450, \"prob\": 0.2, \"notes\": \"Economic slowdown and margin pressure.\" },\n \"base\": { \"target_price\": 480, \"prob\": 0.6, \"notes\": \"Steady growth and stable valuation multiples.\" },\n \"bull\": { \"target_price\": 520, \"prob\": 0.2, \"notes\": \"Accelerated adoption and margin expansion.\" }\n },\n \"method_notes\": \"Valuation based on forward P/E and growth assumptions. Expected return near zero, hence HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI_Equity_Research_Analyst", "risks": [ "Economic downturn reducing capital expenditure.", "Increased competition eroding market share.", "Regulatory changes impacting operations.", "Rising interest rates increasing debt costs.", "Execution risks from acquisitions." ], "ticker": "TMO", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady growth and stable valuation multiples.", "target_price": 480 }, "bear": { "prob": 0.2, "notes": "Economic slowdown and margin pressure.", "target_price": 450 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption and margin expansion.", "target_price": 520 } }, "confidence": 0.6, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": 0.05, "terminal_multiple": 20, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Biopharma industry growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin stability", "impact": "MED", "direction": "POS" }, { "driver": "High P/E and PEG ratios", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt levels and interest rates", "impact": "MED", "direction": "NEG" }, { "driver": "Technological innovation in lab equipment", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory environment in healthcare", "impact": "LOW", "direction": "NEG" }, { "driver": "Global economic conditions affecting spending", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on forward P/E and growth assumptions. Expected return near zero, hence HOLD. Not investment advice.", "current_price": 503.46, "recommendation": "HOLD", "thesis_bullets": [ "Steady revenue growth in life sciences sector.", "High valuation multiples relative to earnings growth.", "Strong market position and diversified portfolio.", "Moderate margin expansion potential exists.", "Balanced risk-reward at current price levels." ], "target_price_6m": 490, "target_price_12m": 480 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 467, "createdAt": "2026-04-09T05:21:57.374Z", "usage": { "inputTokens": 2182, "outputTokens": 3524, "costUsd": 0.002091 } }, { "id": "cmnr15aq006ixp6583nyduq88", "runId": "cmnr15apy06iup6587po5goft", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"TMO\",\n \"currency\": \"USD\",\n \"current_price\": 503.46,\n \"target_price_6m\": 530.00,\n \"target_price_12m\": 562.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"TMO's scale and end-to-end capabilities provide a wide economic moat in life sciences.\",\n \"Biopharma funding headwinds are stabilizing, setting up a gradual revenue growth recovery.\",\n \"Strong free cash flow generation of $5.5B supports ongoing M&A and shareholder returns.\",\n \"Valuation at 23.5x forward P/E is reasonable relative to historical averages and peers.\",\n \"Risks include prolonged destocking in bioprocessing and macroeconomic pressures on equipment spend.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biopharma R&D Funding\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Bioprocessing Destocking Trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"PPD Integration & Synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Academic & Government Budgets\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"China Market Demand\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A Capital Deployment\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"FX Headwinds\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged weakness in early-stage biotech funding.\",\n \"Slower than expected recovery in China end-markets.\",\n \"Integration risks from recent large acquisitions.\",\n \"Foreign exchange volatility impacting reported growth.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.055,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.075,\n \"terminal_multiple\": 24.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 420.00,\n \"prob\": 0.25,\n \"notes\": \"Biopharma funding contracts further and China demand remains depressed, compressing multiples.\"\n },\n \"base\": {\n \"target_price\": 562.00,\n \"prob\": 0.6,\n \"notes\": \"Gradual end-market recovery drives mid-single-digit growth and steady margin expansion.\"\n },\n \"bull\": {\n \"target_price\": 650.00,\n \"prob\": 0.15,\n \"notes\": \"Robust biotech funding rebound and strong margin execution drive multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 25x forward P/E and DCF (7.5% WACC, 24x terminal multiple). Target implies ~11.6% upside, supporting a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "Prolonged weakness in early-stage biotech funding.", "Slower than expected recovery in China end-markets.", "Integration risks from recent large acquisitions.", "Foreign exchange volatility impacting reported growth." ], "ticker": "TMO", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Gradual end-market recovery drives mid-single-digit growth and steady margin expansion.", "target_price": 562 }, "bear": { "prob": 0.25, "notes": "Biopharma funding contracts further and China demand remains depressed, compressing multiples.", "target_price": 420 }, "bull": { "prob": 0.15, "notes": "Robust biotech funding rebound and strong margin execution drive multiple expansion.", "target_price": 650 } }, "confidence": 0.7, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.055, "terminal_multiple": 24, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Biopharma R&D Funding", "impact": "HIGH", "direction": "POS" }, { "driver": "Bioprocessing Destocking Trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "PPD Integration & Synergies", "impact": "MED", "direction": "POS" }, { "driver": "Academic & Government Budgets", "impact": "MED", "direction": "POS" }, { "driver": "China Market Demand", "impact": "MED", "direction": "NEG" }, { "driver": "M&A Capital Deployment", "impact": "MED", "direction": "POS" }, { "driver": "FX Headwinds", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on a blend of 25x forward P/E and DCF (7.5% WACC, 24x terminal multiple). Target implies ~11.6% upside, supporting a BUY rating. Not investment advice.", "current_price": 503.46, "recommendation": "BUY", "thesis_bullets": [ "TMO's scale and end-to-end capabilities provide a wide economic moat in life sciences.", "Biopharma funding headwinds are stabilizing, setting up a gradual revenue growth recovery.", "Strong free cash flow generation of $5.5B supports ongoing M&A and shareholder returns.", "Valuation at 23.5x forward P/E is reasonable relative to historical averages and peers.", "Risks include prolonged destocking in bioprocessing and macroeconomic pressures on equipment spend." ], "target_price_6m": 530, "target_price_12m": 562 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 23282, "createdAt": "2026-04-09T05:21:57.374Z", "usage": { "inputTokens": 2554, "outputTokens": 871, "costUsd": 0.01556 } }, { "id": "cmnr15aq006ivp6581almm9q3", "runId": "cmnr15apy06iup6587po5goft", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"TMO\",\"currency\":\"USD\",\"current_price\":503.46,\"target_price_6m\":516,\"target_price_12m\":528,\"recommendation\":\"HOLD\",\"confidence\":0.64,\"thesis_bullets\":[\"Bioprocessing and pharma tools demand should normalize from post-COVID destocking.\",\"Consumables, services, and diagnostics support resilient cash generation.\",\"Margin recovery potential exists, but current valuation already discounts much of it.\",\"Balance sheet is manageable, though leverage limits aggressive M&A flexibility.\",\"Shares look near fair value unless growth reaccelerates beyond mid-single digits.\"],\"key_drivers\":[{\"driver\":\"Pharma/biotech capex recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Bioproduction normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Recurring consumables mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Clinical research demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Productivity-led margin expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Elevated valuation multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Academic/government funding pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Leverage and deal integration\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Biotech funding recovery stalls\",\"Pricing pressure in instruments\",\"Further multiple compression\",\"Regulatory or reimbursement setbacks\",\"Integration missteps on acquisitions\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.195,\"wacc\":0.082,\"terminal_multiple\":24.5},\"scenarios\":{\"bear\":{\"target_price\":420,\"prob\":0.25,\"notes\":\"Recovery stays muted and valuation de-rates further.\"},\"base\":{\"target_price\":528,\"prob\":0.5,\"notes\":\"Demand improves gradually with modest margin expansion.\"},\"bull\":{\"target_price\":610,\"prob\":0.25,\"notes\":\"Bioprocessing rebounds faster and premium multiple holds.\"}},\"method_notes\":\"Base case uses a forward P/E and EV/EBIT blend on mid-single-digit growth and modest margin recovery. 12M target implies about 4.9% upside, so HOLD fits the rubric. Snapshot quote/fundamentals were kept authoritative; no consensus price targets used. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Model Recommendation v2", "risks": [ "Biotech funding recovery stalls", "Pricing pressure in instruments", "Further multiple compression", "Regulatory or reimbursement setbacks", "Integration missteps on acquisitions" ], "ticker": "TMO", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Demand improves gradually with modest margin expansion.", "target_price": 528 }, "bear": { "prob": 0.25, "notes": "Recovery stays muted and valuation de-rates further.", "target_price": 420 }, "bull": { "prob": 0.25, "notes": "Bioprocessing rebounds faster and premium multiple holds.", "target_price": 610 } }, "confidence": 0.64, "assumptions": { "wacc": 0.082, "revenue_cagr_3y": 0.06, "terminal_multiple": 24.5, "ebit_margin_target": 0.195 }, "key_drivers": [ { "driver": "Pharma/biotech capex recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Bioproduction normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Recurring consumables mix", "impact": "MED", "direction": "POS" }, { "driver": "Clinical research demand", "impact": "MED", "direction": "POS" }, { "driver": "Productivity-led margin expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Elevated valuation multiple", "impact": "HIGH", "direction": "NEG" }, { "driver": "Academic/government funding pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Leverage and deal integration", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Base case uses a forward P/E and EV/EBIT blend on mid-single-digit growth and modest margin recovery. 12M target implies about 4.9% upside, so HOLD fits the rubric. Snapshot quote/fundamentals were kept authoritative; no consensus price targets used. not investment advice", "current_price": 503.46, "recommendation": "HOLD", "thesis_bullets": [ "Bioprocessing and pharma tools demand should normalize from post-COVID destocking.", "Consumables, services, and diagnostics support resilient cash generation.", "Margin recovery potential exists, but current valuation already discounts much of it.", "Balance sheet is manageable, though leverage limits aggressive M&A flexibility.", "Shares look near fair value unless growth reaccelerates beyond mid-single digits." ], "target_price_6m": 516, "target_price_12m": 528 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0f590275dbf21b2c0069d75de5795081969f986664d5fbced5", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 32478, "createdAt": "2026-04-09T05:21:57.374Z", "usage": { "inputTokens": 2455, "outputTokens": 1752, "costUsd": 0.028824 } }, { "id": "cmnr15aq006iyp658nqoqfqv6", "runId": "cmnr15apy06iup6587po5goft", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"TMO\",\n \"currency\": \"USD\",\n \"current_price\": 503.46,\n \"target_price_6m\": 535,\n \"target_price_12m\": 565,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Leads in life science tools with diversified revenue base\",\n \"Stable FCF supports R&D and strategic acquisitions\",\n \"Biopharma R&D recovery drives mid-single digit growth\",\n \"High valuation with PEG above 4 limits near-term upside\",\n \"Margin expansion offsets softer instrument demand\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biopharma R&D spending recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"EBIT margin expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Acquisition synergies (e.g. PPD)\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Innovation in analytical instruments\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Slow biotech funding environment\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"High valuation multiple contraction\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"FX and supply chain volatility\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Debt burden in higher rate era\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged slowdown in biopharma capex\",\n \"Valuation contraction on missed growth\",\n \"Acquisition integration challenges\",\n \"Rising interest expense on $18B debt\",\n \"Competition in specialty diagnostics\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.21,\n \"wacc\": 0.082,\n \"terminal_multiple\": 22\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 460,\n \"prob\": 0.3,\n \"notes\": \"Extended biotech funding winter hits growth and multiples.\"\n },\n \"base\": {\n \"target_price\": 565,\n \"prob\": 0.5,\n \"notes\": \"Steady 6.5% growth, margin gains, and stable valuation.\"\n },\n \"bull\": {\n \"target_price\": 650,\n \"prob\": 0.2,\n \"notes\": \"AI-driven drug discovery accelerates demand and multiples.\"\n }\n },\n \"method_notes\": \"DCF using 6.5% rev CAGR, 21% EBIT margin, 8.2% WACC, 22x terminal EV/EBITDA. Modest 12% upside supports BUY per rubric; not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI Equity Research Model", "risks": [ "Prolonged slowdown in biopharma capex", "Valuation contraction on missed growth", "Acquisition integration challenges", "Rising interest expense on $18B debt", "Competition in specialty diagnostics" ], "ticker": "TMO", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady 6.5% growth, margin gains, and stable valuation.", "target_price": 565 }, "bear": { "prob": 0.3, "notes": "Extended biotech funding winter hits growth and multiples.", "target_price": 460 }, "bull": { "prob": 0.2, "notes": "AI-driven drug discovery accelerates demand and multiples.", "target_price": 650 } }, "confidence": 0.62, "assumptions": { "wacc": 0.082, "revenue_cagr_3y": 0.065, "terminal_multiple": 22, "ebit_margin_target": 0.21 }, "key_drivers": [ { "driver": "Biopharma R&D spending recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "EBIT margin expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Acquisition synergies (e.g. PPD)", "impact": "MED", "direction": "POS" }, { "driver": "Innovation in analytical instruments", "impact": "MED", "direction": "POS" }, { "driver": "Slow biotech funding environment", "impact": "HIGH", "direction": "NEG" }, { "driver": "High valuation multiple contraction", "impact": "MED", "direction": "NEG" }, { "driver": "FX and supply chain volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Debt burden in higher rate era", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using 6.5% rev CAGR, 21% EBIT margin, 8.2% WACC, 22x terminal EV/EBITDA. Modest 12% upside supports BUY per rubric; not investment advice.", "current_price": 503.46, "recommendation": "BUY", "thesis_bullets": [ "Leads in life science tools with diversified revenue base", "Stable FCF supports R&D and strategic acquisitions", "Biopharma R&D recovery drives mid-single digit growth", "High valuation with PEG above 4 limits near-term upside", "Margin expansion offsets softer instrument demand" ], "target_price_6m": 535, "target_price_12m": 565 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "9d644627-09a3-984e-b94e-45816323c642", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 16190, "createdAt": "2026-04-09T05:21:57.374Z", "usage": { "inputTokens": 2782, "outputTokens": 2605, "costUsd": 0.047421 } } ] } }